Stock Watch: The Two Sides Of A Complete Response Letter
Acadia Comes Out Guns Blazing While The FDA’s Hands Are Tied
Executive Summary
The FDA’s rejection of Acadia’s label expansion into a broader patient population for its only approved drug resulted in an aggrieved reaction. Better disclosure from both sides would have helped.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: Digging Holes And Clutching At Straws In Biotech R&D
Biotech CEOs often express surprise when the FDA rejects their drugs. But collaborative interactions between regulators and drug sponsors count for little if the latter fail to adjust their clinical and regulatory efforts accordingly.
Stock Watch: Can Acadia’s Rett Syndrome Drug Succeed?
In a rare disease indication, clinical trial efficacy in Phase III should be the ticket to successful sales. But safety issues warrant careful consideration.